{"id":9318,"date":"2013-10-01T06:20:44","date_gmt":"2013-10-01T10:20:44","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=9318"},"modified":"2013-10-01T09:49:11","modified_gmt":"2013-10-01T13:49:11","slug":"cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318","title":{"rendered":"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/01\/2013 (wallstreetpr) &#8211; On September 30,\u00a0CytRx Corporation (NASDAQ:CYTR) announced results from its Phase 2 test it had conducted on cancer patients to address soft tissue sarcoma. The results showed that patients treated with target drug \u201caldoxorubicin\u201d had responded better to treatment by over 22% as compared to their responses when treated by existing traditional chemotherapy agent doxorubicin. The target drug was also found to spread in an improved but narrow and focused range with in the human body in pharmacokinetics trial. The company additionally highlighted the better survival rates among animals which were treated by \u201caldoxorubicin\u201d in comparison to being treated by doxorunicin.<\/p>\n<p style=\"text-align: justify;\"><b>Modalities of the test\u2019s conducted<\/b><\/p>\n<p style=\"text-align: justify;\">These positive responses from the Phase 2b clinical trials was based on independent radiology observations in a \u201cblinded reading of tumour scans\u201d of patients who were being treated by administering \u201caldoxorubicin\u201d at 3.5 times dosage in comparison to doxorubicin.<\/p>\n<p style=\"text-align: justify;\">The announcements from yesterday further disclosed that treatments based on \u201cGlioblastoma Model\u201d had revealed significant improvement in survival rates. This test related to human glioblastoma cells being implanted in the brain of \u201cimmunologically deficient\u201d mice. These subject mice were observed to survive 63 days more when treated by \u201caldoxorubicin\u201d. In comparison these animals lasted only 25 days when they were treated by doxorubicin.<\/p>\n<p style=\"text-align: justify;\"><b>CytRx announced launch of two new Phase 2 trails<\/b><\/p>\n<p style=\"text-align: justify;\">Based on the positive outcomes from these above trials, the company has gone ahead and registered with FDA for expanding trials on 28 patients suffering from \u201cunresectable glioblastoma\u201d and have not responded to treatment from traditional drug \u201ctemozolomide\u201d. The firm also announced its intentions to start phase 2 clinical trials over the next three months to evaluate the efficacy of treating patients suffering from AIDS induced Kaposi sarcoma with \u201caldoxorubicin\u201d<\/p>\n<p style=\"text-align: justify;\">The company stock saw its value drop by over 4.44% during trading on September 30 in spite of positive news from its Phase 2 trails.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/01\/2013 (wallstreetpr) &#8211; On September 30,\u00a0CytRx Corporation (NASDAQ:CYTR) announced results from its Phase 2 test it had conducted on cancer patients to address [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":9321,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3160,3158,3159],"stock_ticker":[],"class_list":["post-9318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cytrx-corporation","tag-cytrx-corporation-nasdaqcytr","tag-nasdaqcytr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/01\/2013 (wallstreetpr) &#8211; On September 30,\u00a0CytRx Corporation (NASDAQ:CYTR) announced results from its Phase 2 test it had conducted on cancer patients to address [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-10-01T10:20:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2013-10-01T13:49:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial\",\"datePublished\":\"2013-10-01T10:20:44+00:00\",\"dateModified\":\"2013-10-01T13:49:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg\",\"keywords\":[\"CytRx Corporation\",\"CytRx Corporation (NASDAQ:CYTR)\",\"NASDAQ:CYTR\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\",\"name\":\"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg\",\"datePublished\":\"2013-10-01T10:20:44+00:00\",\"dateModified\":\"2013-10-01T13:49:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318","og_locale":"en_US","og_type":"article","og_title":"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial  - Wall Street PR","og_description":"Boston, MA 10\/01\/2013 (wallstreetpr) &#8211; On September 30,\u00a0CytRx Corporation (NASDAQ:CYTR) announced results from its Phase 2 test it had conducted on cancer patients to address [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-10-01T10:20:44+00:00","article_modified_time":"2013-10-01T13:49:11+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial","datePublished":"2013-10-01T10:20:44+00:00","dateModified":"2013-10-01T13:49:11+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg","keywords":["CytRx Corporation","CytRx Corporation (NASDAQ:CYTR)","NASDAQ:CYTR"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318","name":"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg","datePublished":"2013-10-01T10:20:44+00:00","dateModified":"2013-10-01T13:49:11+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/37.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-progress-in-its-phase-2-trial-9318#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"CytRx Corporation (NASDAQ:CYTR) progress in its Phase 2 trial"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/9318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=9318"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/9318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/9321"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=9318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=9318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=9318"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=9318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}